Originally developed in the early 1990s by Professor Frank Ng and colleagues at Monash University in Australia, this peptide was engineered to isolate the lipolytic (fat-metabolizing) properties of growth hormone while eliminating its growth-promoting, diabetogenic, and IGF-1-stimulating effects
Research Use Only Important Legal Notice Used solely for in vitro experiments and cannot be: Used in clinical trials involving humans Administered to humans as part of an experiment or investigation, Supplied to another party for human investigational use
Videos should show: the procedure carried out and, if available, photographic documentation of the pre- and post-treatment situation and the long-term result
Preclinical and early human data suggest it may promote lipolysis, inhibit lipogenesis, and preferentially act on adipose tissue by influencing beta3 adrenergicmediated pathways and hormonesensitive lipase activity
It's whether the research question justifies the added complexity